While t(4;14) MMCLs and patient samples exhibit notable sensitivity to statins (47), our data extend statin utility to non-t(4;14) multiple myeloma by combination with BH3 mimetics where PUMA, NOXA, and ATF4 are biomarkers for statin sensitivity. The gene discussed is ATF4; the disease is plasma cell myeloma.